Title:
ONCOLYTIC VIRUS WITH IMPROVED SAFETY AND ANTICANCER EFFECTS
Document Type and Number:
WIPO Patent Application WO/2020/263059
Kind Code:
A1
Abstract:
The present invention relates to an oncolytic virus with improved safety and anticancer effects, and a use thereof. The oncolytic virus with improved safety and anticancer effects according to the present invention can express an HSV-TK fragment which contains an effector domain composed of a minimum amino acid sequence capable of phosphorylating GCV or ACV while having no thymidine kinase (TK) activity, or a variant thereof to phosphorylate GCV or ACV, thereby killing cancer cells infected with the oncolytic virus and even neighboring cancer cells. In addition, GCV or ACV is involved in the suppression of viral proliferation and thus, can regulate virus-induced side effects even upon the administration of a high dose of the virus. Furthermore, an anticancer effect is increased even though the number of viral particles is reduced due to suppression of GCV against viral proliferation. Therefore, the oncolytic virus with improved safety and anticancer effects according to the present invention can be advantageously used for treating cancer.
More Like This:
| WO/2022/013139 | METHOD OF PURIFYING WHOLE VIRUS PARTICLES |
| WO/2014/194132 | ADENO-ASSOCIATED VIRUS VARIANTS AND METHODS OF USE THEREOF |
| JP2007254475 | DIAGNOSTIC AGENT FOR NANBV |
Inventors:
HWANG TAEHO (KR)
CHO MONG (KR)
CHO MONG (KR)
Application Number:
PCT/KR2020/008472
Publication Date:
December 30, 2020
Filing Date:
June 29, 2020
Export Citation:
Assignee:
BIONOXX INC (KR)
International Classes:
C12N7/00; A61K31/522; A61K35/768; A61K38/45; A61P35/00; C12N9/12
Domestic Patent References:
| WO2014153258A2 | 2014-09-25 |
Foreign References:
| KR20070032786A | 2007-03-22 | |||
| KR20190059421A | 2019-05-31 | |||
| KR20190080806A | 2019-07-08 |
Other References:
NCBI. Genbank : QCY51967.1 (12 June 2019). See entire document.
MARCO REDAELLI, VALENTINA FRANCESCHI, ANTONIO CAPOCEFALO, DOMENICO D'AVELLA, LUCA DENARO, SANDRO CAVIRANI, CARLA MUCIGNAT-CARETTA,: "Herpes simplex virus type 1 thymidine kinase–armed bovine herpesvirus type 4–based vector displays enhanced oncolytic properties in immunocompetent orthotopic syngenic mouse and rat glioma models", NEURO-ONCOLOGY, OXFORD UNIVERSITY PRESS, US, vol. 14, no. 3, 1 March 2012 (2012-03-01), US, pages 288 - 301, XP055623090, ISSN: 1522-8517, DOI: 10.1093/neuonc/nor219
OLIVER W ET AL., HUMAN GENE THERAPY, vol. 10, no. 16, 1999
LAMBRIGHT ES ET AL., GENE THER, vol. 8, pages 946 - 53
See also references of EP 3992281A4
MARCO REDAELLI, VALENTINA FRANCESCHI, ANTONIO CAPOCEFALO, DOMENICO D'AVELLA, LUCA DENARO, SANDRO CAVIRANI, CARLA MUCIGNAT-CARETTA,: "Herpes simplex virus type 1 thymidine kinase–armed bovine herpesvirus type 4–based vector displays enhanced oncolytic properties in immunocompetent orthotopic syngenic mouse and rat glioma models", NEURO-ONCOLOGY, OXFORD UNIVERSITY PRESS, US, vol. 14, no. 3, 1 March 2012 (2012-03-01), US, pages 288 - 301, XP055623090, ISSN: 1522-8517, DOI: 10.1093/neuonc/nor219
OLIVER W ET AL., HUMAN GENE THERAPY, vol. 10, no. 16, 1999
LAMBRIGHT ES ET AL., GENE THER, vol. 8, pages 946 - 53
See also references of EP 3992281A4
Attorney, Agent or Firm:
FIRSTLAW P.C. (KR)
Download PDF:
Previous Patent: AMINOCYANOPYRIDINE DERIVATIVE AND USE THEREOF
Next Patent: ANTENNA STRUCTURE AND ELECTRONIC DEVICE INCLUDING THE SAME
Next Patent: ANTENNA STRUCTURE AND ELECTRONIC DEVICE INCLUDING THE SAME